Glumin XR 500mg extended-release tablets
Ferron Par Pharmaceuticals
Ingredients in every extended-release tablet
|Metformin HCL||500 mg|
Each package contains
|ATC Level 1||A – Alimentary tract and metabolism|
|ATC Level 2||A10 – Drugs Used in Diabetes|
|ATC Level 3||A10B – Blood Glucose Lowering Drugs; excl. Insulins|
17 YEARS OLD AND ABOVE
GLUMIN XR® should generally be given once daily with the evening meal and should be started at a low dose, with gradual dose escalation. Subsequent dosage should be adjusted according to the patient’s therapeutic response, using the lowest possible effective dosage. GLUMIN XR® must be swallowed whole and never crushed or chewed.
In adults, the usual starting dose of GLUMIN XR® is 500 mg once daily with the evening meal. Maximum recommended daily dose in adults is 2,000 mg.
Dosage increases should be made in increments of 500 mg weekly, up to a maximum of 2,000 mg once daily with the evening meal. If glycemic control is not achieved on GLUMIN XR® 2,000 mg once daily, a trial of GLUMIN XR® 1,000 mg twice daily should be considered.
0 TO 17 YEARS OLD
Safety and effectiveness of GLUMIN XR® in pediatric patients have not been established. GLUMIN XR® is not recommended in pediatric patients below the age of 17 years.
Caution is advised in elderly patients because of the reduced renal function. Hence renal function should be monitored regularly.
As mono– or combined therapy with sulphonylurea in patients with Non-insulin-dependent diabetes mellitus (type 2 diabetes) especially if overweight and whose blood glucose level cannot be controlled by diet alone.
As an adjuvant therapy in insulin-dependent diabetic patients with hardly controlled symptoms.